• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU
Click for more information
2.04% $15.52

NEUREN PHARMACEUTICALS LIMITED - Charts / Financials

Market Cap $1.983B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

refresh Created with Sketch. REFRESH
Last update - 15.59pm 23/08/2024 (20 minute delay) ?
Day
Open $15.19   Day High $15.62   Day Low $15.11
Daily Volume 558411
Bids   Sellers
Number Price Volume   Number Price Volume
1 $15.48 440   1 $15.54 752

Directors & Senior Management

Mr. Jonathan Charles Pilcher Chief Executive Officer, Managing Director, Executive Director
Ms. Lauren Frazer Chief Financial Officer, Company Secretary
Mr. Larry Glass Chief Science Officer
Dr. Clive Blower Vice President - Product Development
Mr. Gerry Zhao Vice President - Corporate Development
Ms. Liza Squires Chief Medical Officer
Mr. Patrick Donald Davies Non-Executive Independent Chairman of the Board
Ms. Dianne Angus Non-Executive Independent Director
Mr. Joseph Basile Non-Executive Independent Director
Dr. Jenny Lee Harry Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
$15.52 		Change
0.310(2.04%) 		Mkt cap ! $1.983B
Open High Low Value Volume
$15.19 $15.62 $15.11 $8.655M 558.4K

Buyers (Bids)

No. Vol. Price($)
1 440 $15.48
 

Sellers (Offers)

Price($) Vol. No.
$15.54 752 1
View Market Depth
Last trade - 16.10pm 23/08/2024 (20 minute delay) ?
Last
$15.51 		  Change
0.310 ( 2.25 %)
Open High Low Volume
$15.15 $15.62 $15.15 100416
Last updated 15.59pm 23/08/2024 ?

Top Stories

The business of sport: Warren Tredrea's take on this week's news

Former Port Adelaide AFL star – turned media personality – Warren Tredrea and co-host Jack Hudson explore money in sport.
Reporting wrap: Inghams, Accent, Mayne Pharma Inghams Group Ltd, Accent Group Ltd and Mayne Pharma Group Ltd all reported final year results for the 2024 fiscal year.
Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings A southward cluster of outcropping pegmatites on-site Chariot Corporation's (ASX:CC9) flagship Black Mountain hard rock lithium project has led management and geotechs to sign off on a promising future drilling target for the company as exploration on-site gathers pace.
Raiden gears up for exploration in final quarter of 2024 Raiden Resources Ltd - which is exploration for a multiplicity of minerals in the Pilbara region of WA - is looking ahead to a busy schedule.
The Rising Tide: How institutional adoption is shaping the future of crypto This year's institutional demand for Bitcoin supports stability & credibility for the asset class. We look at what's happened since crypto ETFs were approved in the US & what that means for Australian investors.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.